Rolapitant — Drug Monograph

Brand names: Varubi

Drug class: Supportive Care Agent

Mechanism of Action

Selective, long-acting NK1 receptor antagonist. Rolapitant has an exceptionally long half-life (~180 hours, ~7 days), providing sustained NK1 blockade across the entire delayed CINV window (24–120+ hours post-chemotherapy). Unlike aprepitant, rolapitant does not inhibit CYP3A4 — eliminating the need for dexamethasone dose adjustment.

FDA Indications

• Prevention of delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic chemotherapy, in combination with other antiemetics
• Prevention of delayed nausea and vomiting associated with moderately emetogenic chemotherapy and combinations of anthracyclines and cyclophosphamide (AC regimens), in combination with other antiemetics

Common Side Effects

• Decreased appetite
• Neutropenia
• Hiccups
• Dizziness

Clinical Pearl

Rolapitant's clinical niche is its lack of CYP3A4 inhibition — unlike aprepitant and netupitant, it does not require dexamethasone dose reduction. However, its potent CYP2D6 and BCRP inhibition and very long half-life (~7 days) mean drug interactions can persist across cycles. Crucially, do not administer more frequently than every 14 days — this is frequently overlooked in dose-dense regimens.

Related Therapies & Mechanisms

• Aprepitant (Emend) — Supportive Care Agent
• Avatrombopag (Doptelet) — Supportive Care Agent
• Darbepoetin Alfa (Aranesp) — Supportive Care Agent
• Defibrotide (Defitelio) — Supportive Care Agent